Certified by Founder
Lodge
Adcendo
start up
Denmark
- Copenhagen, Capital Region of Denmark
- 26/11/2024
- Series B
- $135,000,000
Adcendo seeks to develop antibody-drug conjugates to create new medicines for cancer patients with a significant unmet need.
The company was founded in 2017 in Copenhagen, as a spin-out from The Finsen Laboratory of Rigshospitalet and the University of Copenhagen.
- Industry Biotechnology Research
- Website https://adcendo.com/
- LinkedIn https://www.linkedin.com/company/adcendo/
Derapi | $7,000,000 | (Feb 4, 2026)
MaiaEdge | $20,000,000 | (Feb 4, 2026)
enclaive | $4,849,418 | (Feb 4, 2026)
Graici | $7,500,000 | (Feb 4, 2026)
Arbor(US) | $6,300,000 | (Feb 4, 2026)
ecovia I bio | Undisclosed Amount | (Feb 4, 2026)
Prenosis | $20,000,000 | (Feb 3, 2026)
Linq | $20,000,000 | (Feb 3, 2026)
Breezy | $10,000,000 | (Feb 3, 2026)
Poetiq | $45,800,000 | (Feb 3, 2026)
JJG Machining Group | $30,000,000 | (Feb 3, 2026)